Therapeutics

PF-06852231

Overview

Name: PF-06852231
Therapy Type: Small Molecule (timeline)
Target Type: Cholinergic System (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Pfizer

Background

PF-06852231 is a small-molecule cholinergic modulator. No preclinical information about this compound is published.

Findings

In July 2017, Pfizer began enrolling healthy volunteers for a safety, tolerability, and pharmacokinetics study of this compound at the company's clinical research unit in Brussels. In January 2018, Pfizer announced it was discontinuing its research and development work across neuroscience indications, and this compound was discontinued.

As of January 31, 2018, clinicaltrials.gov still showed this trial as enrolling; however, the Pfizer Pipeline of January 30, 2018, lists it as discontinued. 

Last Updated: 02 Feb 2018

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

External Citations

  1. clinicaltrials.gov
  2. Pfizer Pipeline of January 30, 2018,

Further Reading

No Available Further Reading